Enter your Information and Unlock Premium Video

DR. STEVEN A. SHEARDOWN | Advancing therapeutics against novel targets for CNS diseases

27.09.2022

Views

Cerevance is a private pharmaceutical company focused on central nervous system diseases. Its proprietary NETSseq technology enables the company to produce comprehensive transcriptional profiles of specific brain cell types from mature human brain tissue. Steven will describe the rationale for this approach, how the NETSseq method works, and how Cerevance has used the Trio RNA-Seq Library Preparation Kit to generate good data from difficult materials. To date, the company has produced over 5,000 high quality, cell type-specific datasets from control and disease tissues, and is well positioned to deliver life-changing therapeutics for patients who have brain-related disorders.